DiNAQOR AG entered into a collaboration and license agreement with BioMarin Pharmaceutical Inc
3 May 2020 – BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that the company has entered into a preclinical collaboration and license agreement with DiNAQOR AG (DiNAQOR), a gene therapy platform company, to develop novel gene therapies to treat rare genetic cardiomyopathies. DiNAQOR will receive an undisclosed upfront payment and is eligible to receive development, regulatory and commercial milestones on product sales in addition to tiered royalties on worldwide sales. The commercial terms of this landmark transaction were not disclosed.
DiNAQOR was founded and is led by several leading pharmaceutical and biotechnology executives and academics with deep cardiology and gene therapy expertise.
Walder Wyss advised DiNAQOR on all legal aspects of the transaction, including corporate, IP and life science issues. The team was led by Hans Rudolf Trüeb (Partner, IP/IT) and included Marion Bähler (Senior Associate, Corporate/M&A) and Florian C. Roth (Associate, IP/IT).